Committed to babies and their health
Clinically proven to improve health outcomes of critically ill preemies
Committed to scientific and clinical research in breast milk
Prolact Product Safety

Reimbursement Considerations

Payor Consideration:

  • Diagnosis-related Group (DRG).
  • Tax Equity and Fiscal Responsibility Act (TEFRA) of 1982.
  • Cost-outlier (high costs or exceptionally long stays).
  • Stop-Loss Insurance consideration.
  • Letter of Medical Necessity (pre-authorization).
  • Prolact+ H2MF®, Prolact+ 4®, Prolact+ 6®, Prolact+ 8® and Prolact+ 10® supplement for High Risk Infant.
  • Chargeable item, not to be confused with complimentary human milk fortifier (cow milk-based).
  • Intended for 1-3% of all births.

Follow Us!

Contact Us